Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;16(11):708-716.
doi: 10.1111/crj.13543. Epub 2022 Sep 29.

Challenges of vaccination and herd immunity in COVID-19 and management strategies

Affiliations
Review

Challenges of vaccination and herd immunity in COVID-19 and management strategies

Jun She et al. Clin Respir J. 2022 Nov.

Abstract

Coronavirus disease 2019 (COVID-19), the highly contagious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide with millions of cases and more than 5 million deaths to date. SARS-CoV-2 has caused serious damage all over the world with many countries experiencing the third or the fourth wave of the viral disease outbreaks, mainly due to the emergence of mutant variants. Those who unvaccinated remain most vulnerable to COVID-19 and its variants. COVID-19 vaccination, along with prevention strategies, is a critical measure to defense against the disease. COVID-19 vaccination can reduce the spread of virus and help protect susceptible population. Although herd immunity might not be realized solely by vaccination, COVID-19 vaccines have been proved to be effective in reducing the risk of severe disease, hospitalization, and even death. It is recommended that people get vaccinated as soon as they are eligible. This review summarizes the recent SARS-CoV-2 variants that brought challenges for vaccination and herd immunity and discusses promising management strategies.

Keywords: COVID-19; SARS-CoV-2; herd immunity; prevention; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Similar articles

Cited by

References

    1. WHO Coronavirus (COVID‐19) Dashboard. Accessed 29 Nov. 2021. https://covid19.who.int/
    1. She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 Novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med. 2020;9(1):19. doi:10.1186/s40169-020-00271-z - DOI - PMC - PubMed
    1. Kaur SP, Gupta V. COVID‐19 Vaccine: A comprehensive status report. Virus Res. 2020;288:198114. doi:10.1016/j.virusres.2020.198114 - DOI - PMC - PubMed
    1. WHO Coronavirus (COVID‐19) Dashboard. Accessed 29 Nov. 2021. https://covid19.who.int/table
    1. Cascella M, Rajnik M, Aleem A, et al. Features, evaluation, and treatment of coronavirus (COVID‐19). In: StatPearls. Treasure Island: StatPearls Publishing; 2021. Jan. - PubMed

Substances

Supplementary concepts